GPCR antitarget modeling: pharmacophore models for biogenic amine binding GPCRs to avoid GPCR-mediated side effects.
about
In silico elucidation of the molecular mechanism defining the adverse effect of selective estrogen receptor modulatorsBinding of protein kinase inhibitors to synapsin I inferred from pair-wise binding site similarity measurementsA novel structural framework for α(1A/D)-adrenoceptor selective antagonists identified using subtype selective pharmacophoresIdentification of structural features in chemicals associated with cancer drug response: a systematic data-driven analysis.Recent trends and observations in the design of high-quality screening collections.Pharmacophore modelling: applications in drug discovery.Predictive in silico off-target profiling in drug discovery.Phenyl Ether- and Aniline-Containing 2-Aminoquinolines as Potent and Selective Inhibitors of Neuronal Nitric Oxide Synthase.Quantitative prediction of antitarget interaction profiles for chemical compounds.Exploring the ligand-protein networks in traditional chinese medicine: current databases, methods, and applicationsToward deciphering the code to aminergic G protein-coupled receptor drug design.Novel approach for efficient pharmacophore-based virtual screening: method and applications.Self-organizing molecular fingerprints: a ligand-based view on drug-like chemical space and off-target prediction.Synthesis and structure evaluation of new complex butylarylpiperazin-1-yl derivatives.Identification of the Beer Component Hordenine as Food-Derived Dopamine D2 Receptor Agonist by Virtual Screening a 3D Compound DatabasePutting small molecules in the lead.A systematic study of chemogenomics of carbohydrates.Experimental validation of in silico target predictions on synergistic protein targets
P2860
Q28471679-038636DF-AF17-46BB-BD9A-97942C84EFF5Q28475132-D0F6FA25-C811-48A8-80F8-B4F76E4D965AQ28478109-2B1FE81A-5C4B-48FD-A3AB-BB8BE1F357AFQ30845301-6CF261BD-F5CC-4DF1-9611-D04D86FB14B6Q33893113-F3866BF7-6C8F-4ED6-9285-0B3E6F807EB8Q34621241-3F368DCF-94B1-44CC-BE79-2E3CA407397CQ35103940-792927F8-F0AF-414C-B789-5F3D50A42242Q36277787-4FFDF066-F86A-4AAB-B80F-AC44EBDCB84AQ36501098-996470D3-F922-48DE-B698-14BFDA7AD664Q36933260-9FEF5F3B-14F1-4231-B618-B261D9FD3BAAQ37269754-55C5AF20-C394-43C1-833C-4419BE8C59C6Q37399793-0A454A90-FAEF-47FB-9B1A-39AE1EF2D87CQ39991328-26F139E2-EAD8-4906-A505-A67AFD15753AQ41897055-A2CC7A43-5AAE-41EA-B439-25E15443C3D5Q42317202-0CEB1D18-79AE-414F-80FB-094149B4D9E9Q52935238-26320064-1C4C-4BEA-A5EA-43B48F67173EQ53631411-ADF3BFD3-F92C-45F6-9FC8-28831626ABE3Q58023059-637A2C54-4719-41D4-8D1D-4ADBE6F01CCC
P2860
GPCR antitarget modeling: pharmacophore models for biogenic amine binding GPCRs to avoid GPCR-mediated side effects.
description
2005 nî lūn-bûn
@nan
2005 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
GPCR antitarget modeling: phar ...... id GPCR-mediated side effects.
@ast
GPCR antitarget modeling: phar ...... id GPCR-mediated side effects.
@en
type
label
GPCR antitarget modeling: phar ...... id GPCR-mediated side effects.
@ast
GPCR antitarget modeling: phar ...... id GPCR-mediated side effects.
@en
prefLabel
GPCR antitarget modeling: phar ...... id GPCR-mediated side effects.
@ast
GPCR antitarget modeling: phar ...... id GPCR-mediated side effects.
@en
P2860
P356
P1433
P1476
GPCR antitarget modeling: phar ...... id GPCR-mediated side effects.
@en
P2093
Andreas Evers
Thomas Klabunde
P2860
P304
P356
10.1002/CBIC.200400369
P577
2005-05-01T00:00:00Z